Open an account

Verve Therapeutics

VERV · NASDAQ

Price unavailable right now.

No price history for this range.

About VERV

Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company is headquartered in Boston, Massachusetts and currently employs 274 full-time employees. The firm is focused on developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The Company’s lead programs include VERVE-102, VERVE-201, and VERVE-301, which target the three cholesterol drivers of atherosclerosis: LDL-C, remnant cholesterol, and Lp(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high LDL-C levels. VERVE- 201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia. VERVE-301 is designed to permanently turn off the LPA gene to reduce Lp(a) levels.

Employees
274
Headquarters
Boston, Massachusetts
Listed
Jun 17, 2021
Sector
Health Care
Industry
Biotechnology
Website
vervetx.com

VERV key statistics

This section is temporarily unavailable. Refresh to try again.

VERV earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 20.6% on average.

  1. Q2 FY23: reported -$0.87 per share against an estimate of -$0.9364
  2. Q3 FY23: reported -$0.72 per share against an estimate of -$0.9364
  3. Q4 FY23: reported -$0.69 per share against an estimate of -$0.8384
  4. Q1 FY24: reported -$0.59 per share against an estimate of -$0.7273
  5. Q2 FY24: reported -$0.59 per share against an estimate of -$0.6977
  6. Q3 FY24: reported -$0.59 per share against an estimate of -$0.7109
  7. Q4 FY24: reported -$0.58 per share against an estimate of -$0.7099
  8. Q1 FY25: reported -$0.35 per share against an estimate of -$0.6687

VERV news

  • Vandana Singh

    What's Happening With French Biotech Abivax Stock On Wednesday?

  • Press releasePRNewswire

    Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

  • Press releasePRNewswire

    Lilly and Verve announce expiration of Verve tender offer

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VERV, CTLP, SAGE on Behalf of Shareholders

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VERV, SAGE, CTLP, COLB on Behalf of Shareholders

  • Press releaseBusiness Wire

    VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV

  • Vandana Singh

    Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst

  • 5 Analysts Assess Verve Therapeutics: What You Need To Know

Similar companies

Companies in the same industry as Verve Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.